|
Volumn 33, Issue 21, 2015, Pages 2406-2408
|
Is progression-free survival the right end point in trials of patients with clearly resectable, borderline resectable, and unresectable liver-limited colorectal cancer?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CETUXIMAB;
FLUOROURACIL;
FOLINIC ACID;
IRINOTECAN;
OXALIPLATIN;
ANTINEOPLASTIC AGENT;
RAS PROTEIN;
BORDERLINE RESECTABLE LIVER LIMITED COLORECTAL CANCER;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER PATIENT;
CANCER SURGERY;
CANCER SURVIVAL;
CLEARLY RESECTABLE LIVER LIMITED COLORECTAL CANCER;
COLORECTAL LIVER METASTASIS;
DRUG INFUSION;
FOLLOW UP;
HUMAN;
INOPERABLE CANCER;
LETTER;
LONG TERM SURVIVAL;
OVERALL SURVIVAL;
PREOPERATIVE TREATMENT;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
SURVIVAL RATE;
TREATMENT FAILURE;
UNRESECTABLE LIVER LIMITED COLORECTAL CANCER;
CLINICAL PRACTICE;
COLORECTAL NEOPLASMS;
FEMALE;
GENETICS;
LIVER NEOPLASMS;
MALE;
PATHOLOGY;
SECONDARY;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
COLORECTAL NEOPLASMS;
FEMALE;
HUMANS;
LIVER NEOPLASMS;
MALE;
PHYSICIAN'S PRACTICE PATTERNS;
RAS PROTEINS;
|
EID: 84940388245
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2014.60.7044 Document Type: Letter |
Times cited : (5)
|
References (7)
|